Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00945009 · OUTCOME

Event-Free Survival (EFS)

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor · Source last updated 2026-06-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Probability
Interval / dispersion
95% Confidence Interval
Time frame
4 years from study enrollment

What was measured

Probability of no relapse, secondary malignancy, or death whichever occurs first

Analysis population: All eligible BWT patients. 6 patients were excluded due to ineligibility and 6 patients were excluded due to protocol violation.

Groups in this outcome

Arm 1 (Bilateral Wilms Tumors)

Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy. Dactinomycin: Given IV Doxorubicin Hydrochloride: Given IV Radiation Therapy: Undergo radiation therapy Therapeutic Conventional Surgery: Undergo surgical resection Vincristine Sulfate: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm 1 (Bilateral Wilms Tumors)189

Reported measurements

Source class 1
Values in Probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm 1 (Bilateral Wilms Tumors)0.82Not reported0.740.91Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.74
        upper Limit
        0.91
        value
        0.82
denoms
  1. counts
    1. group Id
      OG000
      value
      189
    units
    Participants
description
Probability of no relapse, secondary malignancy, or death whichever occurs first
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy. Dactinomycin: Given IV Doxorubicin Hydrochloride: Given IV Radiation Therapy: Undergo radiation therapy Therapeutic Conventional Surgery: Undergo surgical resection Vincristine Sulfate: Given IV
    id
    OG000
    title
    Arm 1 (Bilateral Wilms Tumors)
param Type
MEAN
population Description
All eligible BWT patients. 6 patients were excluded due to ineligibility and 6 patients were excluded due to protocol violation.
reporting Status
POSTED
time Frame
4 years from study enrollment
title
Event-Free Survival (EFS)
type
PRIMARY
unit Of Measure
Probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice